Aaron Y. Mochizuki, DO
- Pediatric Neuro-Oncologist, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
About
Biography
As a pediatric neuro-oncologist, I treat patients with brain tumors as well as other solid tumors. I seek to provide compassionate care to each person and their family.
The awe-inspiring children going through the most challenging circumstances and their incredible families who support them inspired me to pursue my career.
My research examines how brain tumor immune-cell populations change with therapy and how those changes can predict treatment response.
In my free time, I enjoy running, hiking and snowboarding.
Medical School: A.T. Still University, Mesa, AZ, 2013.
Internship: University of Hawaii, Honolulu, HI, 2014.
Residency: LAC+USC Medical Center, Los Angeles, CA, 2016.
Fellowship: Pediatric Hematology/Oncology, UCLA, Los Angeles, CA, 2019.
Fellowship: Pediatric Neuro-Oncology, Stanford University, Palo Alto, CA, 2021.
Board Certifications: General Pediatrics, 2016; Pediatric Hematology/Oncology, 2021.
Interests
Pediatric neuro-oncology; immunotherapy
Services and Specialties
Brain Tumor Center
Interests
Data science; tumor microenvironment
Research Areas
Oncology
Publications
Pediatric Embryonal Tumors. Neuro-Oncology Compendium for the Boards and Clinical Practice. : Oxford University Press (OUP); Oxford University Press (OUP); 2023.
CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology. 2023; 25:i11.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603:934-941.
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 2021; 12:6938.
A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. Frontiers in Oncology. 2021; 11:744739.
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research. 2020; 26:5232-5245.
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clinical Cancer Research. 2019; 25:1913-1922.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine. 2019; 25:477-486.
Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. Frontiers in Immunology. 2019; 10:121.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2023 Cincinnati Children's Hospital Medical Center. All rights reserved.
